Welcome to our dedicated page for Jaguar Health SEC filings (Ticker: JAGX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Jaguar Health, Inc. (NASDAQ: JAGX) SEC filings page on Stock Titan aggregates the company’s regulatory disclosures, giving investors structured access to its capital markets activity and material agreements. Jaguar is a commercial-stage pharmaceuticals company focused on plant-based prescription medicines for gastrointestinal distress in humans and animals, and its filings provide insight into how it finances and supports these programs.
Recent Form 8-K filings describe a range of transactions, including secured and unsecured promissory notes, royalty interest agreements and amendments, PIPE financings involving Series N Perpetual Preferred Stock and common stock with pre-funded warrants, and privately negotiated exchanges of preferred stock for common shares and pre-funded warrants. Other 8-Ks outline at-the-market offering amendments, conditional approval-related developments for Canalevia-CA1, and note purchase agreements backed by deposit account control arrangements and subsidiary guarantees.
Jaguar’s proxy materials, such as definitive proxy statements on Schedule 14A, detail stockholder proposals to approve share issuances under Nasdaq Listing Rule 5635(d), including common stock issuable upon exchange of Series L, Series M, and Series N preferred stock and upon conversion of certain convertible promissory notes and related warrants. These documents also explain voting rights, voting caps for preferred series, and the structure of special and annual meetings.
On this page, users can review Jaguar’s 10-K and 10-Q reports (when available) for broader business and risk disclosures, while Form 4 and related ownership filings provide visibility into insider equity transactions. Stock Titan enhances these filings with AI-powered summaries that highlight key terms in complex documents, such as interest rates, maturity dates, collateral arrangements, voting provisions, and share issuance conditions. Real-time updates from EDGAR ensure that new Jaguar Health filings, including 8-Ks announcing material events, are quickly accessible with plain-language explanations.
Jaguar Health, Inc. reported that Nasdaq staff notified the company it is out of compliance with the exchange’s listing rules following a recent reverse stock split. After a 1-for-35 reverse split of its common stock effective April 30, 2026, the company has approximately 401,226 publicly held shares.
This falls below Nasdaq Listing Rule 5550(a)(4), which requires at least 500,000 publicly held shares, creating an additional basis for potential delisting from The Nasdaq Capital Market. Jaguar must present its views on this new deficiency to the Nasdaq Hearings Panel in writing by May 8, 2026.
Nasdaq staff also noted the company remains out of compliance with the minimum $1.00 bid price requirement. If Jaguar cannot cure the publicly held shares deficiency and then demonstrate a closing bid price of at least $1.00 per share for a minimum of 10 consecutive business days, its securities may be delisted from Nasdaq.
Jaguar Health has called its 2026 annual stockholder meeting for May 22, 2026 to elect one Class II director, ratify RBSM LLP as auditor, and vote on several financing proposals.
The company is seeking approval under Nasdaq Listing Rule 5635(d) to issue more than 19.99% of its common stock to C/M Capital Master Fund through a proposed $40 million equity line of credit and a separate preferred stock financing. Jaguar plans an equity line allowing sales of common stock up to $40 million plus 2% in commitment shares, and a private placement of Series P Non-Convertible Preferred Stock with $2.4 million stated value sold for $2.0 million, along with $72,000 of commencement shares. Both structures could significantly dilute existing holders if fully utilized, though C/M Capital’s ownership would be capped at 4.99%, or 9.99% with notice.
Jaguar Health received a decision from the Nasdaq Hearings Panel allowing its shares to remain listed, provided it regains compliance with Nasdaq’s bid price rule. To do this, the company must achieve a closing bid of at least $1.00 per share for 10 consecutive business days on or before May 15, 2026.
To help reach this threshold, Jaguar is implementing a 1‑for‑35 reverse stock split of its common stock, effective April 30, 2026, with trading to continue on a split‑adjusted basis on The Nasdaq Capital Market under the symbol JAGX. Every 35 existing shares will convert into one share, with no change in par value and no fractional shares issued; cash will be paid instead of fractions.
The reverse split also proportionately adjusts outstanding options, warrants, and equity plan reserves, but does not change the total number of authorized common or preferred shares. The Panel will retain jurisdiction over Jaguar until September 1, 2026, and the company may be delisted if it fails to meet the bid price requirement or other Nasdaq rules.
Jaguar Health, Inc. is asking stockholders to approve, pursuant to Nasdaq Listing Rule 5635(d), the potential issuance of Common Stock to C/M Capital Master Fund, LP that could exceed 19.99% of shares outstanding. The proxy seeks approval for two financings: an equity line of credit to sell up to $40,000,000 of Common Stock and a private preferred-stock purchase (Series P) tied to up to $2,400,000 stated value, plus $72,000 in Commencement Shares. Shares outstanding were 14,044,277 as of April 15, 2026. The filings describe mechanics, limits (a 4.99% beneficial ownership cap, increaseable to 9.99% by notice), registration rights, dilution examples at various prices, and a board-backed proposal to allow adjournment to solicit additional proxies for these approvals.
Jaguar Health, Inc. increased its authorized share capacity following approval at a Special Meeting of stockholders held on April 20, 2026. Stockholders approved a Tenth Amendment to the company’s Third Amended and Restated Certificate of Incorporation to raise authorized voting common stock from 298,000,000 shares to 500,000,000 shares. The total number of shares the company is authorized to issue rose from 352,475,074 shares to 554,475,074 shares. The board approved this Authorized Share Increase and filed the Tenth Amendment with the Delaware Secretary of State, where it became effective immediately upon filing. All five proposals presented at the Special Meeting were approved, with 7,181,767 shares represented out of 12,419,277 shares entitled to vote as of the March 2, 2026 record date.
Jaguar Health, Inc. reports that it previously had a stockholders’ deficit of approximately $18.7 million as of December 31, 2025, which did not satisfy Nasdaq Listing Rule 5550(b)(1) requiring at least $2.5 million in stockholders’ equity.
The company now believes its stockholders’ equity as of April 7, 2026 exceeded $2.5 million, after a series of transactions. These include $16.0 million of non-dilutive capital under a License Agreement with Napo Pharmaceuticals, Woodward Specialty and Future Pak, $3.0 million received after termination of a buy-back provision, and approximately $1.0 million from Woodward’s purchase of existing product inventory under a Supply Agreement.
Additional items are $2.0 million to be received upon satisfaction of Third Party Replacement MSA Conditions, approximately $1.2 million to be received from Mytesi product sales under a Firm Order, about $0.2 million from earlier Mytesi net sales, roughly $0.2 million of grant revenue, and an approximate $3.4 million gain on partial extinguishment of debt owed to affiliates of Chicago Venture Partners, L.P. The company cautions that these are forward-looking statements subject to risks discussed in its 2025 Form 10-K.
Jaguar Health reported 2025 results showing slightly lower sales but much higher losses, while also securing new licensing cash. Net product revenue for the year was $11.5 million, down about 1.5% from 2024. Loss from operations widened to $45.9 million from $30.8 million, and net loss attributable to common stockholders grew to $53.6 million from $38.5 million. Non-GAAP EBITDA was a loss of $48.2 million, larger than the $36.0 million non-GAAP EBITDA loss in 2024. The company noted net revenue rose 5% in the fourth quarter versus the third quarter of 2025.
In January 2026, Jaguar received an upfront payment of $16 million in non-dilutive capital under a U.S. license agreement with Future Pak for its crofelemer drugs Mytesi and Canalevia-CA1, with an additional $2 million payable upon post-closing conditions and $3.0 million already received of up to $20 million in potential milestone and other future payments. The company plans to appeal Nasdaq’s March 5, 2026 noncompliance determination related to Nasdaq Listing Rule 5550(a)(2) at a hearing on April 7, 2026, and delisting is stayed pending the panel’s final decision.
Jaguar Health, Inc. details a diversified gastrointestinal drug business built around crofelemer and related plant-derived therapies. The company licensed U.S. rights to Mytesi and Canalevia-CA1 to Future Pak in January 2026, receiving $16 million in non‑dilutive capital plus a further $2 million tied to post‑closing conditions and eligibility for up to $20 million in milestones. An additional $3.0 million payment followed termination of a buy‑back provision, while Jaguar retains manufacturing responsibilities.
The filing highlights advanced development of a highly concentrated crofelemer powder for oral solution targeting ultra‑rare intestinal failure indications, including microvillus inclusion disease and short bowel syndrome with intestinal failure, supported by multiple orphan drug designations in the U.S. and EU and early proof‑of‑concept data showing parenteral support reductions of up to 37%. Jaguar also pursues NP‑300 for infectious diarrhea with potential access to a tropical disease priority review voucher, markets Gelclair for oral mucositis under a U.S. in‑license, and develops plant‑based mental health drugs through the Magdalena joint venture.
Jaguar Health, Inc. notified the SEC that it could not timely file its Annual Report on Form 10-K for the fiscal year ended December 31, 2025 due to delays compiling material subsequent-event information. The company states it will file the Form 10-K no later than the fifteenth calendar day following the prescribed due date.